z-logo
Premium
Methamphetamine‐induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatment
Author(s) -
Volz Trent J.,
Fleckenstein Annette E.,
Hanson Glen R.
Publication year - 2007
Publication title -
addiction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.424
H-Index - 193
eISSN - 1360-0443
pISSN - 0965-2140
DOI - 10.1111/j.1360-0443.2007.01771.x
Subject(s) - dopamine transporter , dopaminergic , nucleus accumbens , methamphetamine , dopamine , monoamine neurotransmitter , vesicular monoamine transporter 2 , striatum , vesicular monoamine transporter , neuroscience , dopamine plasma membrane transport proteins , pharmacology , addiction , medicine , psychology , serotonin , receptor
ABSTRACT Aim  To review studies delineating the neurotoxic effects of methamphetamine on monoamine transport in dopaminergic neurons of the striatum and nucleus accumbens. Method  The scope of this review includes the English language dopamine transporter and vesicular monoamine transporter‐2 primary literature to April 2006 identified by Pubmed, Science Citation Index and SciFinder Scholar literature searches. Results  Changes in the function of the plasmalemmal dopamine transporter and the vesicular monoamine transporter‐2 are key components of methamphetamine‐induced persistent dopaminergic deficits. These deficits include persistent reductions in dopamine content, dopamine transporter density and tyrosine hydroxylase activity. The striatum is susceptible to these effects of methamphetamine while the nucleus accumbens is resistant. Differences in dopamine transporter density and activity, extracellular dopamine levels and antioxidant levels in these two brain regions may, in part, account for the resistance of the nucleus accumbens. Conclusion  These findings concerning the nature of methamphetamine‐induced changes in plasmalemmal and vesicular dopamine transport have very important implications for drug targets and for understanding the etiology of dopaminergic neurodegenerative processes, such as those associated with methamphetamine addiction and Parkinson's disease.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here